Anish Sheth, MD
Gastroenterology · Princeton, NJNPI 1336235191
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Johnson & Johnson at 31.8% of the total. Reporting peaked in 2019 at $60,650 and has fallen 75.2% since, to $15,069 in 2025. Among gastroenterology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 547 payments — averaging $276.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$48K
- Medical Device Business Services, Inc.$24K
- Covidien LP$24K
- Phathom Pharmaceuticals, Inc.$21K
- Ferring Pharmaceuticals Inc.$20K
- Celltrion USA Inc.$5K
- plus $9K from 37 others
What the payments were for
- Consulting fees$69,85446%
- Speaking & faculty fees$61,56341%
- Travel & lodging$8,2185%
- Food & beverage$10,9877%
- Education$6250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$151,247 in reported general payments places this provider in the 95th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 11 | $316,048 |
| RinvoqUpadacitinib | 13 | $162,409 |
| XifaxanRifaximin | 30 | $99,339 |
| LinzessLinaclotide | 28 | $29,248 |
| VoqueznaVonoprazan Fumarate | 27 | $18,960 |
| TrulancePlecanatide | 16 | $18,130 |
| Adalimumab-Fkjp(Cf) PenAdalimumab-Fkjp | 11 | $11,008 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 31 | $5,364 |
| CholestyramineCholestyramine (With Sugar) | 44 | $3,120 |
| Famotidine | 185 | $2,656 |
| Ursodiol | 13 | $2,181 |
| Opium Tincture | 18 | $1,998 |
| Colestipol Hcl | 21 | $1,595 |
| Omeprazole | 100 | $1,182 |
| Esomeprazole Magnesium | 43 | $1,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $48,124 | $316,04811 claims |
| AbbVieRinvoq, Linzess | $2,940 | $191,65641 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $502 | $117,46846 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $21,372 | $18,96027 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $19,853 | $5,36431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Princeton
- Amy ShriverPrinceton$121K
- Vinod RustgiNew Brunswick$431K
- Zamir BrelviNewark$391K
- Adam ElfantMount Laurel$385K
- Devjit NayarHoboken$258K
- Lea ChenNew Brunswick$185K
- Alexander PerelmanWest Orange$160K
- Barry KaufmanEgg Harbor Township$157K
- Ramesh GuptaFair Lawn$143K
- Sanket PatelVoorhees$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.